An impressive force of 424 advocates from all 50 states reached every Congressional office during the 2019 NACDS RxIMPACT Day on Capitol Hill. The 2019 program – held March 5-6 – empowered and inspired pharmacy advocates from across the nation to visit Capitol Hill to further advance health policy solutions. In addition to the event’s importance in advocating for pro-patient and pro-pharmacy issues, the 2019 NACDS RxIMPACT Day on Capitol Hill served as the site for the announcement of several grassroots and political awards and recognitions.
“NACDS pharmacy advocates did an amazing job of taking to the entire Congress recommendations on the issues that affect patients in neighborhoods across America. Just as pharmacists are highly trusted sources of health and wellness information for patients, these advocates are highly trusted sources of policy solutions for members of Congress. We had outstanding conversations on our key issues and we appreciate the energy and commitment of NACDS members and the engagement of members of Congress and their staff.” – NACDS President and CEO Steven C. Anderson, IOM, CAE
- With a patient-focused agenda, NACDS members discussed with members of the U.S. Senate and U.S. House of Representatives the threat of direct and indirect remuneration (DIR) fees and the urgency for reform.
- NACDS members also discussed opportunities for pharmacists to provide additional services given their extensive education, and discussed additional ways to build on longstanding and ongoing efforts to help address opioid abuse and addiction.
- Douglas Read, director of pharmacy and regulatory affairs, H-E-B, received the 2019 NACDS RxIMPACT Key Contact of the Year Award.
- The Kroger Co. received the 2019 NACDS RxIMPACT Leader of the Year Award, which was accepted by Nick Gonzales, health and wellness compliance officer and chief HIPAA privacy officer.
- The NACDS Political Action Committee (NACDS-PAC) presented two Chairman’s Inner Circle Awards, to: Mike Duteau, vice president of business development and strategic relations, Kinney Drugs, Inc.; and to Ed Kaleta, vice president of federal government relations and U.S. public policy, Walgreen Co.